SELLAS Life Sciences reported its Q3 2026 financial results and provided updates on its clinical pipeline. The most significant disclosure is the imminent release of topline Phase 3 REGAL trial results for GPS in AML, which could be a major catalyst for the stock.
SELLAS Life Sciences announced its third-quarter 2026 financial results, showing a healthy cash position of $134.7 million. The primary focus of the filing, however, is the upcoming announcement of topline primary endpoint results for its Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) this month. This is a critical near-term catalyst for the company, as positive results could significantly de-risk the asset and drive substantial stock appreciation, while negative results would likely lead to a sharp decline. Additionally, updates on the Phase 2 trial of tambiciclib (SLS009) in AML and plans for pancreatic cancer development provide further pipeline context, but the Phase 3 AML data is the immediate market mover. Traders should be aware of the binary nature of the upcoming Phase 3 data release.